Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-On the radar: Corporate top news overload

Wed, 30th Oct 2019 07:37

* European shares seen opening little changed

* Fiat Chrysler and PSA confirm tie-up talks

* Bank earnings in focus: DB, CS, StanChart, Santander

* Federal Reserve seen cutting rates, focus on policy outlook
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your
thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net

ON THE RADAR: CORPORATE TOP NEWS OVERLOAD (0736 GMT)

Futures have opened sideways with no clear directional trend in Europe.

What's clear however is that there is such a huge flow of corporate news that it will be
difficult to be sure not to have missed anything before the open and the market, which tends to
be quite unforgiving these days, gives its verdict.

Before getting in the Q3 action, let's first flag out a major piece of news in the auto
industry with Fiat Chrysler confirming talks with French rival PSA for a
potential tie-up.

News of the tentative merger comes as Germany's Volkswagen lowered its full-year
outlook for vehicle deliveries, warning of slowing demand.

Lots to take in the banking industry too:

Deutsche Bank reports 832 million euro Q3 loss on restructuring

StanChart flags growth, interest rate headwinds after Q3 profit beat

Credit Suisse doubles Q3 net profit

Santander Q3 net profit falls 75% as UK charges offset Brazil strength

But there are heavyweights across all sectors making headlines this morning so in no
particular order, he's the rest of the top news: click here to get it on Eikon:

Airbus cuts delivery goal on Hamburg plant snags

Record Q3 output boosts Total's cash flow, low prices hit profit

Lower oil and gas prices weigh on OMV Q3 profit

Bayer says number of glyphosate plaintiffs jumps to 42,700

Clariant Q3 profit and sales fall as economic climate worsens

Angry Birds maker Rovio's Q3 profit halves year-on-year

EssilorLuxottica confirms 2019 targets after stronger Q3 sales

Britain's Next keeps full year guidance after Q3 sales rise

(Julien Ponthus)

*****

FED WATCHING, Q3 GALORE AND THE XMAS BREXIT ELECTION (0542 GMT)

Christmas will come early to the UK this year, precisely on December 12 in the form of a UK
general election.

It's far from certain however that the polls will deliver anything on Boris Johnson or
Jeremy Corbyn's wish list but less than 48 hours ahead of Halloween, investors aren't spooked by
the prospect of the process going all wrong.

The pound is roughly stable at 1.2870 and according to IG, financial spreadbetters expect
London's FTSE to open just 7 points lower, so nothing dramatic there indeed.

Frankfurt's DAX is also seen retreating slightly at the open by 25 points but Paris is
should be flat.

With Wall Street on and off record highs, the Fed's meeting today and the expected interest
rate cut will be key, especially after it emerged that Washington and Beijing may not complete
their interim trade agreement in time to sign in Chile next month.

Amid all that news let us not forget that we are in for one of the busiest day of the Q3
season with a flurry of results such as Bayer, GlaxoSmithKline, Suez
or Total.

Last but not least, there will also be a deluge of indicators from the euro zone which
should shed more light on whether there is light to be seen at the end of the macro gloom
tunnel.

(Julien Ponthus)

*****
(Reporting by Danilo Masoni, Joice Alves, Julien Ponthus and Thyagaraju Adinarayan)

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.